Navigation Links
FDA Allows Return of Drug for Morning Sickness
Date:4/9/2013

TUESDAY, April 9 (HealthDay News) -- A morning-sickness medication that was withdrawn from the market 30 years ago has won U.S. Food and Drug Administration approval under a new name.

In its new form, the drug -- formerly called Bendectin and now renamed Diclegis -- is the only medication specifically approved to treat the stomach upset many women suffer from during pregnancy.

In the intervening decades between the drug's withdrawal from the market and its re-approval on Tuesday, the medicine has undergone rigorous scrutiny and is now deemed safe by the FDA.

Obstetricians welcomed the announcement.

"The nausea and vomiting of early pregnancy can range from mild to debilitating," said Dr. Jennifer Wu, an obstetrician-gynecologist at Lenox Hill Hospital in New York City. "Patients will welcome more options for treatment with the reintroduction of Bendectin."

Their nausea may not disappear completely, but "it will hopefully decrease to the point that a patient can function," she added.

Diclegis, which combines vitamin B6 and the antihistamine doxylamine, is a delayed-release pill that's meant to be taken daily before symptoms set in. Those symptoms are often worse after waking up, hence the name "morning sickness." But some women are plagued by nausea all day long.

The medication is intended for women whose nausea isn't "adequately managed through recommended changes in diet and lifestyle," Dr. Hylton Joffe, director of the Division of Reproductive and Urologic Products in the FDA's Center for Drug Evaluation and Research, said in an FDA news release.

Morning sickness usually improves after the first trimester. Recommended dietary and lifestyle changes to help beat the nausea include eating several small meals instead of three large meals, eating low-fat bland foods that are easy to digest and avoiding smells that can trigger episodes.

Another expert said the drug's reintroduction was long overdue.

"This drug should have never been taken off the market in the first place," said Dr. Keith Eddelman, director of obstetrics at Mount Sinai Medical Center in New York City. "It is not a controversial drug and the data is very convincing."

Another drug, Zofran, which is approved for nausea in cancer patients, is widely used for pregnancy, Eddelman said. "I think both of these medications are similar in safety," he added.

Bendectin was widely prescribed after its introduction in 1956, but costly lawsuits claiming safety issues caused the drug's maker, Merrell Dow, to pull it from the market in 1983.

Since then the drug has gone through rigorous testing. For this new approval, the FDA studied Diclegis in 261 women experiencing morning-sickness symptoms related to pregnancy. The women were between seven and 14 weeks of pregnancy and were randomly assigned to receive two weeks of treatment with Diclegis or a placebo, the FDA said.

The researchers found that women taking Diclegis experienced greater symptom relief than those taking placebo and missed fewer days of work.

In other studies, the combination of active ingredients in Diclegis were not found to pose an increased risk of danger to the fetus, the FDA said. However, side effects can include severe drowsiness or sleepiness.

Diclegis is marketed by the Quebec-based firm Duchesnay Inc. The company sells a generic version of the pill in Canada under the name Diclectin. U.S. sales of Diclegis are expected to start in June.

Duchesnay has not yet released a price for Diclegis, the Associated Press reported.

More information

The American College of Obstetricians and Gynecologists has more about morning sickness.

-- Margaret Farley Steele

SOURCES: Jennifer Wu, M.D., obstetrician-gynecologist, Lenox Hill Hospital, New York City; Keith Eddelman, M.D., professor, obstetrics, gynecology and reproductive science, human genetics and genomics, and director of obstetrics, Mt. Sinai Medical Center, New York City; U.S. Food and Drug Administration, news release, April 9, 2013; Associated Press


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Simulation technology allows users to safely practice phacoemulsification cataract surgery
2. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
3. Undergoing multiple ACL surgeries allows patients to regain basic function, but not full activity
4. Accuracy of narrow band imaging with colonoscopy allows for distal non-cancerous polyps to be left in place
5. Does gallows humor among physicians encourage accusations of murder and euthanasia?
6. Kinsey Reporter: Free app allows public to anonymously report, share information on sexual behavior
7. Scientists at IRB BARCELONA discover a key process that allows colon cancer to metastasize
8. New technology allows scientists to capture and preserve cancer cells circulating in the bloodstream
9. All Energy Solar Now Allows Clients To Track Solar System Energy Performance
10. Robot allows remote presence in programming brain and spine stimulators
11. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Allows Return of Drug for Morning Sickness
(Date:4/26/2017)... , ... April 26, 2017 , ... ... to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more ... to dairy proteins, providing direct cost savings as well as more stable pricing ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... announces Mirroring360 Pro . This new addition to the Mirroring360 product family ... education and business. , Mirroring360 Pro enables educators, business professionals and individuals to ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... decision-makers are preparing for how his administration could impact the employee benefits industry. ... what changes are most likely to make it through Congress. His discussion will ...
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the ... dispensaries and head shops –can’t help but be heartened by the industry’s current surge. ... odor aptly described as “skunk smell.” At last they can simply, safely and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Global Surgical ... devices are tubes used to remove excess liquid and ... serum, pus, urine, bile or lymph. Surgical drains are ... surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic ... prophylactic post-surgery to prevent accumulation of fluid e.g. blood ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: